Argenx stock falls to EUR 726.20 with USD 50.2 billion market cap

Published on 10/08/2026 at 16:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At EUR 726.20, Argenx stock was down 12.47 percent on October 8, 2026. The prior close was EUR 829.70.

Schwarz-Weiß-Reportagefoto: Forscherin beugt sich konzentriert über ein Mikroskop im Immunologie-Labor, dramatisches Chiaroscuro-Licht, körnige Filmtextur — Argenx NL0010832176 Reportagefoto in Schwarz und Weiß zeigt Wissenschaftlerin bei der Autoimmun-Forschung am Mikroskop, Illustration mit AI erstellt.

Argenx stock fell to EUR 726.20 at Lang & Schwarz at 4:00 p.m. CEST on October 8, 2026. The move was minus 12.47 percent versus the Lang & Schwarz prior close of EUR 829.70, while the company's market capitalization stood at USD 50.2 billion.

Bid and ask show the market

Lang & Schwarz showed a bid of EUR 725.80 and an ask of EUR 726.60 at the same timestamp. The spread was EUR 0.80, giving investors a direct view of the price gap around the latest indication.

The primary listing is on Nasdaq under ticker ARGX, while argenx's investor page also identifies Euronext Brussels as a listing venue through its stock-information section. The Nasdaq quote was USD 807.94 at 10:02 a.m. ET on October 8, 2026, with volume of 489,882 shares against an average volume of 283,404 shares.

Valuation remains measurable

The finance quote showed a trailing P/E ratio of 31.26 and no dividend yield. The same quote placed the Nasdaq 52-week range at USD 661.85 to USD 1,072.75, with the latest USD price inside that band.

According to MarketBeat on October 8, 2026, 24 analysts had an average 12-month target of USD 1,158.61, alongside a high target of USD 1,415.00 and a low target of USD 910.00. The average target was 43.40 percent above the Nasdaq price of USD 807.94, calculated in the same currency.

Comparison with peers

argenx: minus 12.47 percent, P/E 31.26, market capitalization USD 50.2 billion
Nasdaq Composite: , ,
S&P 500: , ,

October reporting date

FinanzNachrichten reported on September 25, 2026 that Goldman Sachs discussed its outlook ahead of argenx's quarterly report on October 22, 2026. That date gives the next scheduled point for a fresh operating update.

Argenx's investor page describes the company as an integrated immunology business and provides access to financial reports, filings and analyst coverage through its investor section.

Price closes below the prior level

At Lang & Schwarz, Argenx was trading at EUR 726.20 on October 8, 2026 at 4:00 p.m. CEST, down 12.47 percent against the prior close of EUR 829.70. The latest market figures place the stock below its October 7 reference level while the Nasdaq valuation remains visible in US dollars. The further course of trading is shown by the continuously updated real-time quote of argenx stock.